Drug intelligence / Profile preview

UP-003

Development stage: Preclinical
Lead developer: U-Ploid Biotechnologies

Overview

UP-003 is an early-stage drug candidate currently in the discovery phase, developed by U-Ploid Biotechnologies. While specific details regarding its molecular target, modality, and primary indication remain undisclosed, the company's broader research focus is on addressing meiotic aneuploidy and chromosome segregation errors in oocytes. This research aims to reduce aneuploidy during in vitro fertilization (IVF) procedures, potentially improving clinical outcomes for patients undergoing fertility treatments.

Beyond the preview

Go deeper on UP-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UP-003.

Explore the full profile